Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Loan Funds F2G's Late-Stage Novel Antifungal

Executive Summary

€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.

You may also be interested in...



Imutex's Universal Flu Vaccine Inches Forward On New Data

The Imutex joint venture between hVIVO and the SEEK Group updates promise of its universal flu vaccine candidate after additional data from a Phase IIb study showed a statistically significant effect on its primary endpoint.

Scrip Asks…What Does 2022 Hold For Biopharma? Part 7: People And Planet

Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.

Scrip Asks…What Does 2022 Hold For Biopharma? Part 6: Digital And Telehealth

Digital and telehealth solutions took off during COVID-19 and industry observers expect them to advance still further in the coming year. Coupling enhanced patient experience with rich opportunities to use associated data to enhance product development and health care practice, benefits should accrue to industry, health care practitioners, health systems and patients alike.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124228

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel